So12 Molecular Therapies - Neuroprotection

Web-Seminar, Deutschland
Webinar

So12 Molecular Therapies - Neuroprotection

Symposiumof the section DOG-genetics, DOG 2020 Online

Datum:
11.10.2020, 13:30 - 11.10.2020, 14:15
Veranstalter:
DOG - Deutsche Ophthalmologische Gesellschaft e.V.
Kurzbeschreibung:
Recent advances in the understanding of the pathogenesis of retinal diseases have paved the way for the development of new therapeutic approaches. Protein homeostasis has been shown to be important in keeping cellular mechanisms functioning, and once this homeostasis is severely affected, survival of the cells is no longer granted, independent of the underlying pathology.
Fortbildungspunkte: 

Fachärzte

Max. Teilnehmer: unbegrenzt
Gebühren ab: 120,00 EUR

Hinweis:
This symposium is part of the DOG congress 2020 (9.-11.2020). The attandance for the total congress costs 250€ for members and 120€ for non-members.

Ärzte/-innen in Weiterbildung

Max. Teilnehmer: unbegrenzt
Gebühren ab: 120,00 EUR

Hinweis:
This symposium is part of the DOG congress 2020 (9.-11.2020). The attandance for the total congress costs 250€ for members and 120€ for non-members.

Studenten/-innen

Max. Teilnehmer: unbegrenzt
Gebühren ab: gebührenfrei

Hinweis:
The full congress is free for students and PhD students.
Bemerkungen:
Diese Veranstaltung findet einmalig statt und bietet Fortbildungsmöglichkeiten für Fachärzte, Ärzte/-innen in Weiterbildung und Studenten/-innen.
Veranstaltungsnummer: 34022
Gebühren ab: gebührenfrei
verfügbare Plätze: unbegrenzt
Sprache: Englisch
 
Vom Veranstalter gemeldetes Programm:

Organisator/Vorsitzender: Knut Stieger | Gießen
Vorsitzender: Marius Adler | Dresden

One important pathway that has re-entered center stage is therefore neuroprotection for which several newly identified regulators of cell survival and viability have been identified. Preclinical studies are promising and the start of first in-human trials are likely to follow soon. The approval of Luxturna gene therapy in Europe in November 2018 has resulted in the treatment of a number of patients all over Europe, but has also shown that legislation and institutional support for this new class of medication can be important hurdles.

 

So12-01
13:30
13:45

Proteome centric target discovery for photoreceptor protection: the p97/VCP story

Due to high production rates in visual pigment and high metabolic activity photoreceptor cells are especially vulnerable to defects in protein homeostasis. The ATPase Valosine Containing Protein (p97/VCP) acts as a protein quality control checkpoint of membrane proteins and binds to rhodopsin before the protein is released from the ER towards plasma membrane localization. Inhibiting VCP ATPase activity pharmacologically, we have generated evidence for a strong and long-lasting rescue of degenerating rod photoreceptors in the RhoP23H transgenic rat suggesting VCP as a target to treat autosomal dominant RP. Protection correlates with restoration of physiological rhodopsin trafficking to rod outer segments, improved rod OS ultrastructure and an improved ERG after intravitreal injection of the inhibitors.

Marius Ueffing | Tübingen

So12-02
13:45
14:00

Retinoic acid receptor inhibitors in retinal diseases

Richard Kramer | Berkeley/USA

So12-03
14:00
14:15

Proteostasis in retinal disease

Ronald Roepman | Nijmegen/NL
Veranstaltungsort:
This symposium is virtual.
Saal von Graefe
Anschrift:

Web-Seminar, Deutschland
Veranstalter:
DOG - Deutsche Ophthalmologische Gesellschaft e.V.
Organisation:

INTERPLAN AG
Congress, Meeting & Event Management AG
Landsberger Straße 155
DE - 80687 München
Tel.: +49 (0)89 548 234 35
Tel.: +49 (0)89 548 234 0
Fax: +49 (0)89 548 234 43
Fax: +49 (0)89 548 234 44

 
Hinweis:

Registration required. Please contact the organizer for further information.